The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
We will study the hypothesis that long-term Tekturna treatment will improve endothelial
function and the production and function of endothelial progenitor cells (EPCs) in patients
with early atherosclerosis. Specifically, long-term Tekturna treatment will increase the
Reactive Hyperemia Peripheral Arterial Tonometry indexes and increase the numbers and the
function of circulating endothelial progenitor cells, compared to placebo, in association
with a reduction in inflammation and oxidative stress.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institute on Aging (NIA) Novartis